Floatz logo

Lidocaine

Substance-Related Disorder

Tanta UniversitySmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Substance-Related Disorder cohort.

Asset / SponsorPhaseRating
Methadone
Rutgers, The State University of New Jersey
Phase 4BBB
HYDROMORPHON
Endeavor Health
Phase 4BBB
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Wake Forest University Health Sciences
Phase 4BBB
Fentanyl
University of Crete
Phase 4BB
Dexmedetomidine
Kaohsiung Veterans General Hospital.
Phase 4BB

View all 26 →

Same molecule, other indications

Lidocaine is also rated in:

peripheral neuropathyActive
BBB
Indicative · Phase 4
79 / 100
View asset →
postherpetic neuralgiaDormant
BBB
Indicative · Phase 4
78 / 100
View asset →
post-operative pain, non-human animalActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →